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days of absenteeism from work were 3.3. Resource consumption
was a little higher in the unsatisfactory glycemic control group
(p < 0.05). This higher consumption was also associated with the
patient’s insulinization and type of diabetes, specially the absen-
teeism from work (p < 0.05); the highest value (12.7 days) was
reported by T1DM patients with unsatisﬁed glycemic control.
CONCLUSIONS: Diabetes involves a large burden to society in
terms of resource consumption and labour absenteeism. Unsat-
isfactory glycemic control and patient’s insulinization was also
associated with a higher resource consumption.
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OBJECTIVES: Determine the direct cost of treatment for
patients with Type II Diabetes (T2D) in Greece. METHODS: In
order to deﬁne the patient management model, a 2-step method-
ology was implemented. First, a questionnaire-based survey was
conducted in a random sample of 51 physicians specializing in
the treatment of T2D, geographically distributed according to
the total population of T2D patients in Greece. Participating
physicians were asked to review their patient records before
completing the questions regarding patient resource utilization
and other speciﬁc treatment parameters. As a second step, the
survey ﬁndings were reviewed by an expert consensus panel for
validation and ﬁnal deﬁnition of the data for the analysis.
Patients were categorized as (a) regulated (i.e. maintaining
glucose levels within therapeutic range for a 1-year period) and
(b) non-regulated. Cost analysis was based on estimation of
1-year direct cost of treatment (physician consultations,
laboratory/diagnostic tests and pharmacotherapy—insulin and
oral hypoglycemic agents), based on 2007 private sector fees and
prices, in Euros. Hospitalization costs were not included.
RESULTS: Average direct cost for regulated patients (46% of
total T2D patient population) was estimated at €983/year, while
for the non-regulated (54%) it was signiﬁcantly higher, at €1570.
For regulated patients, laboratory/diagnostic tests accounted for
43.6%, physician consultations for 21.8% and pharmacotherapy
for 34.6% of the total average cost, whereas for the non-
regulated the respective values were 45.9%, 26% and 28.1%.
Weighted average patient cost was calculated at €1300/year,
resulting in a total cost of approximately 1 billion Euros/year for
the estimated 780,000 T2D patients in Greece. CONCLU-
SIONS: Although not including the cost of hospitalizations and
complications, which account for approximately 2/3 of the total
patient cost, as reported in the literature, this study demonstrated
the importance of blood glucose control/regulation, not only
from the clinical but from the economic perspective as well.
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OBJECTIVES: Describe, in usual care, health care resource uti-
lization and costs associated before and during the ﬁrst 6 months
of insulin therapy in patients with type 2 diabetes (T2D).
METHODS: Pan-european observational study. Here results for
France are reported. The direct costs of diabetes care include
costs of visits to health care professionals, antidiabetic medica-
tions, glucose testing and hospitalizations linked to diabetes.
Costs were calculated by collecting individual resource use and
assigning local units costs (2006). RESULTS: Of the 177 T2D
patients initiated with insulin, 152 (85.9%) patients were fol-
lowed to 6 months. Enrolled patients (male 57%) had mean age
of 64.8 years 11.3 (SD) and mean BMI of 29.4 kg/m2 6.2
(SD). They had been diagnosed with diabetes 13.0  8.1 (SD)
years ago and had a mean HbA1C at insulin initiation of 9.6%
1.9 (SD). Long/intermediate insulin only was the most common
therapy initiated (80.8% of patients). 50.3% of patients were
hospitalized for insulin initiation. At 6 months 86.2% of patients
were taking oral antidiabetics; metformine and sulfamide
(31.6%), metformine only (14.5%) or sulfamide only (13.2%).
During the 6 month follow up, 81.6% of patients visited a
general practitioner, 71.1% a diabetologist and 14.5% had a
hospital admission due to diabetes (median stay = 3.0 days). The
median number of visits to diabetologists was 1 in the 6 months
prior to insulin initiation and 2 in the 6 months following initia-
tion, the median costs of diabetes speciﬁc specialist care increased
from 41 € to 83 €. Median total costs (interquartile range) for the
6 months prior to as well as after insulin initiation were €647
(421–1373) and €805 (579–1213), respectively. CONCLU-
SIONS: Half of the patients were hospitalized for insulin initia-
tion. The median cost of diabetes care increased in the 6 months
following insulin initiation.
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OBJECTIVES: Diabetes is a public health issue of signiﬁcant
economic importance because of the chronic nature and the
serious complications associated with long disease duration. The
aim of the study was to describe the direct medical cost for
average patient with type 2 diabetes and for whole population
of diabetics in Czech Republic using ″bottom-up“ costing
approach. METHODS: The data collection was arranged in
ambulatory diabetologists by speciﬁc questionnaire. Data were
collected between October nad December 2007 and covered a
minimum period of 6 months, retrospectively. Estimates of health
care utilisation and costs were projected for a 12-month period.
The overall direct health care costs were calculated by multiply-
ing the quantities of the resource used with the unit reimburse-
ment of each resource by insurance company. RESULTS: During
the collection phase of the study 495 patient records were gained.
The average HbA1C values were 6.0%, body mass index (BMI)
was 29.9 for men and 31.1 for women and the average blood
presure was 141/80 mm Hg. At least one microvascular compli-
cation is present in 49.29% and at least one macrovascular
complication in 44.24% of type 2 diabetic patients. According to
the type of treatment 10.51% of patents were treated with diet
and exercise, 49.9% were on oral antidiabetic drugs and 39.6%
were on insulin therapy. Hypolipidemic drugs were present in
63.4% and antihypertensive drugs in 82.8% of patients. The
majority of diabetic patients visited ambulatory diabetologist
(98.99%, mean number of visits 2.3), general practitioner
(91.31%, mean number of visits 3) or other ambulatory special-
ist (75.4%), mainly ophthalmology, cardiology or neurology in
last 6 month. In the same time period 16.16% of patients were
hospitalized with average length of stay 13.68 days (1.2 days in
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